skip to main content

CHAARTED Docetaxel mHSPC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardUrological CancersCHAARTED Docetaxel mHSPCSCE Medical Oncology

A patient taking apalutamide 240 mg daily develops an intolerable grade 3 rash without mucosal involvement. After supportive treatment, when and how may apalutamide be resumed according to the SmPC?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Withhold to grade 1 or baseline; resume at 240, 180 or 120 mg daily

For grade 3 or greater or intolerable toxicity, apalutamide is withheld until symptoms improve to grade 1 or baseline. It can then resume at the same dose or a reduced 180 mg or 120 mg dose. Continuing through grade 3, inventing a 60 mg dose, or mandatory permanent cessation after the first event does not follow the SmPC.

Reference: Erleada UK SmPC. https://www.medicines.org.uk/emc/product/9832/smpc